TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03135275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged complete PCI
Description: During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate complete PCI
Description: During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy™ stent
Description: Bioabsorbable Polymer Drug-Eluting Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy™ stent
Description: Bioabsorbable Polymer Drug-Eluting Stent
Study: NCT04350255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty with a Trident II hemispherical cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty with a Trident II hemispherical cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty with a Trident II Tritanium cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty with a Trident II Tritanium cup
Study: NCT05231499

Intervention type: OTHER
Intervention: nasal irrigation
Description: regular saline nasal rinse
Study: NCT04961268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TraMADol 50 Mg Oral Tablet
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 100 MG Oral Tablet
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600Mg Tab
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 600 mg/acetaminophen 1000 mg
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study: NCT01898871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A daily ration of 40 kcal/kg of body weight during 56 days
Description: On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
Study: NCT04077879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1617
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1617
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1617
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02870907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: no post operative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m²/d, IV (in the vein) from D1 to D5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1, 5 mg/m²/d, IV at D1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Orbital irradiation
Description: 45 Grays (Standard or external beam radiotherapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 160 mg/m²/d, IV from D1 to D5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,5 mg/m²/d, IV at D22 and D26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m²/d, IV from D22 to D26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 560 mg/m²/d, IV at D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m²/d, IV from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 160 mg/m²/d,IV from D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 15 mg, intrathecal Thiotepa injection at D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,5 mg/m²/d), IV at D22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1000 mg/m²/d, IV from D22 à D24.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytapheresis
Description: Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC : 7/d, IV from D-8 to D-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 250 mg/m²/d, IV from D -5 to D-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 300 mg/m²/d, IV from D-5 to D-3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral bood stem cell transplantation
Description: at D0
Study: NCT04374669

Intervention type: PROCEDURE
Intervention: Neuroplasty with Racz catheter
Description: The patient is placed in the prone position with a pillow placed under the abdomen to correct the lumbar lordosis. After sterile preparation and draping, the epidural space via the sacral hiatus using a 16 gauge needle is accessed. Then, the Racz catheter is advanced to the site of adhesions under the fluoroscopic guidance. The target site is determined by the location of pathology on lumbar MRI, preprocedural epidurography, and clinical symptoms before the adhesiolysis. Adhesiolysis is performed through the high-volume administration of medications, which consist of a combination of a steroid, local anesthetics, hyaluronidase, and 5% hypertonic saline. As needed, the catheter remains in the epidural space for two days, with the additional injection on each of the days.
Study: NCT03266510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Description: Subjects will perform inspiratory muscle strength training for 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: Subjects will perform sham training for 6 weeks.
Study: NCT01376258

Intervention type: DRUG
Intervention: 5ARI
Description: dutasteride or finasteride

Intervention type: DRUG
Intervention: 5ARI
Description: dutasteride or finasteride
Study: NCT03414983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Specified dose on specified days
Study: NCT01254617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01898871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A daily ration of 40 kcal/kg of body weight during 56 days
Description: On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
Study: NCT00773721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask
Description: Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping.
Study: NCT02433197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic program
Description: The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression.
Study: NCT01699945

Intervention type: OTHER
Intervention: This is an observational study being conducted as a substudy of antoher trial.
Study: NCT02743351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProTmune
Description: Ex-vivo, programmed mobilized peripheral blood (mPB) cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Untreated mobilized peripheral blood (mPB) cells
Study: NCT04641455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Espumisan, N acetylcystein
Description: Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Espumisan, N acetylcystein
Description: Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Administration of water before upper endoscopy
Study: NCT01652742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585 XX
Description: one single dose
Study: NCT02285998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent Influenza Vaccine
Description: Intramuscular injection of vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: Intramuscular injection of vaccine
Study: NCT02566291

Intervention type: DEVICE
Intervention: Success
Description: Success rate and time for insertion

Intervention type: DEVICE
Intervention: Success
Description: Success rate and time for insertion
Study: NCT02705807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOLAN injection with currently marketed diluent
Description: FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen \[pH\] 10.2 - 10.8 diluent) for Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOLAN injection with reformulated diluent
Description: FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
Study: NCT01213420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nivea Cream for scar hydration
Description: 3 applications per day during 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloë Vera FORMULA F-BC-096 for scar hydration
Description: 3 applications per day during 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eucerin Calming cream for scar hydration
Description: 3 applications per day during 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aloë Vera with modified preservative for scar hydration
Description: 3 applications per day during 6 months
Study: NCT04556396

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cone beam CT
Description: On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
Study: NCT03523728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT00199836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51
Study: NCT01037491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole plus aspirin versus rabeprazole plus clopidogrel
Description: The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole plus aspirin versus rabeprazole plus clopidogrel
Description: The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
Study: NCT02375152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Capsulotomy
Study: NCT04512053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-303 18 mg/day
Description: Oral administration for 12 weeks, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration for 12 weeks, once daily
Study: NCT00440479

Intervention type: DRUG
Intervention: Bortezomib
Description: dose as determined (observational study) by treating physician
Study: NCT03044249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-101
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT05464706

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Synchrolevels
Description: Supplement therapy to model the recovery after liver surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synchrolevels
Description: Supplement therapy to model the recovery after liver surgery
Study: NCT02582320

Intervention type: DRUG
Intervention: Ibrutinib
Description: A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
Study: NCT00619255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Trauma Support Program
Description: The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
Study: NCT01848184

Intervention type: DEVICE
Intervention: PARIETEX™ Composite Ventral Patch
Description: PARIETEX™ Composite Ventral Patch for ventral hernia repair
Study: NCT01250340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100 mg/day for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 cp day for 30 days
Study: NCT04521023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantabell Tab
Description: Patients assigned to experimental group are treated with Cantabell Tab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candemore Plus Tab
Description: Patients assigned to experimental group are treated with Candemore Plus Tab
Study: NCT02087956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigation
Description: The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Screening and Referral
Description: Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
Study: NCT03069885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Postoperative dressing
Description: The standard postoperative dressing, using steri strips placed over the suture line.
Study: NCT04536428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with clip
Description: This intervention is performed as the following orders.~* The tip of endoscope is accessed to a bleeding site.~* The accurate visualization of bleeding site is done.~* A sheath of delivery system of clip is inserted through a working channel of endoscope.~* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~* The both ends of clip are placed on both sides of a bleeding site.~* If bleeding is still continued, additional placements of clip are tried until bleeding stops.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hemostasis with clip
Description: This intervention is performed as the following orders.~* The tip of endoscope is accessed to a bleeding site.~* The accurate visualization of bleeding site is done.~* A sheath of delivery system of clip is inserted through a working channel of endoscope.~* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~* The both ends of clip are placed on both sides of a bleeding site.~* If bleeding is still continued, additional placements of clip are tried until bleeding stops.
Study: NCT03292809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol topical ocular, eye drops
Description: Cyclosporine A solution in vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical ocular, eye drops
Description: Vehicle
Study: NCT04040075

Intervention type: DRUG
Group type: OTHER
Intervention: Biktarvy Tab
Description: Antiretroviral drug
Study: NCT00481286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving outcomes using group clinics for older patients
Description: Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for diabetes patients
Study: NCT01702714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: multiple ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: multiple ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: up to 6 cycles
Study: NCT04347915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: Clevudine 120mg once a day for 14 days (up to 21 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo once a day for 14 days (up to 21 days)
Study: NCT03127839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Strengthening
Description: Use of eccentric strengthening exercises in treatment plan during visits and at home.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Strengthening
Description: Use of eccentric strengthening exercises in treatment plan during visits and at home.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Strengthening
Description: Use of traditional strengthening exercises in treatment plan during visits and at home.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Strengthening
Description: Use of traditional strengthening exercises in treatment plan during visits and at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain education
Description: Addition of pain neuroscience-focused education in addition to strengthening exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain education
Description: Addition of pain neuroscience-focused education in addition to strengthening exercise program